Fundamental of Pharmacokinetics
Dr. Stefano Persiani is currently Director of Translational Sciences and Pharmacokinetics at Rottapharm Biotech, Italy. He graduated in Pharmacy at the University of Milan, Italy, and completed a Post-Doctoral fellowship in the Department of Pathology of the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA, and later as a Research Associate in the Department of Pharmaceutics of the University of Southern California, School of Pharmacy in Los Angeles, California, USA. After these academic positions, he entered the pharmaceutical industry at Farmitalia Carlo Erba, Pharmacia, Upjohn, and Zambon Group and in the CRO sector as Scientific Director for Clinical Pharmacology. Dr. Persiani in his current role applies translational approaches from drug discovery to development and registration in several therapeutic areas. Dr. Persiani is a member of various international scientific societies and serves on the review board of numerous professional journals. Dr. Persiani acts as an external expert evaluator for the European Commission on the 7th Framework Program, Maria Sklodowska-Curie Individual Fellowships, HORIZON 2020, and Innovative Medicine Initiative. Dr. Persiani is also an expert evaluator for La Caixa Foundation where he evaluates and provides recommendations to the bank on applications requesting funding. Dr. Persiani is a faculty of Pharmaceutical Training International and Traininng.com where he provides training to pharmaceutical executives in several fields of Translational Sciences.
The webinar reviews the general concepts and basic elements of pharmacokinetics. The webinar will describe the processes that a drug undergoes after administration such as the absorption (when not administered intravenously), the distribution, including plasma protein binding, the metabolism (the bio-transformation of the drug into its metabolites), and the excretion (via the bile in faces and via the kidney in urine). The use of PK during drug development will also be described. PK studies can facilitate knowledge management and decision-making to streamline drug discovery and development and to reduce the attrition rate.
Pharmacokinetics are fundamental throughout drug discovery and development. The assessment of the pharmacokinetic profile on new chemical entities reduces the failure during development making the process more efficient.
- Volume of distribution
- Plasma protein binding
- Elimination half-life
Course Level - Basic
Who Should Attend
Project managers, pre-clinical and clinical pharmacologists, regulatory affairs, clinical research associates, drug discovery scientists, contract research organizations, medical writers, graduate students willing to enter the drug R&D sector.
Why Should You Attend
To get a better understanding of the different aspects that contribute to the pharmacokinetic profile of a new chemical entity. PK studies assess drug exposure to facilitate drug development. PK studies offer great support to learn and confirm the key characteristics of new molecular entities in a quantitative manner. This provides evidence for optimizing drug development plans and enabling critical decision-making. Drug development without PK is considered at a higher risk of failure.